The prevalence of thyroid pathology among pregnant women in Ukraine (2003-2016) and the possibility of its prevention

Authors: L.F. Matyukha, O.V. Protsyuk, O.V. Lynchak


The objective

To determine the prevalence of thyroid pathology among pregnant women during 2003–2016. and studies of the effect of the use of the complex Yodofol containing potassium iodide (200 μg) and folic acid (400 mg) in the ultrasound parameters of the thyroid gland (T) of women.

Materials and methods

Used f. 21 «Report on medical care for pregnant women, parturient women and puerperas». We examined more than 1 million pregnant women who were under the supervision of antenatal clinics during 2003–2016. The frequency was calculated per 1000 pregnant women.

Results

The prevalence of thyroid diseases that were or occurred during pregnancy and complicating pregnancy, childbirth and the postpartum period in Ukraine in 2003–2016. was 64.47 ± 0.08 per 1000 pregnant women under the supervision of antenatal clinics, including the prevalence of diffuse goiter I degree – 45.77 ± 0.07. The prevalence of thyroid disease among pregnant women decreased by 25.40% – from 72.78 ± 0.14 in 2003–2007. to 57.64 ± 0.09 ‰ in 2013–2016 (p<0.001), and diffuse goiter of I degree by 21.17% – from 50.13 ± 0.12 in 2003–2007. to 41.37 ± 0.12 ‰ in 2013–2016 (p<0.001).

Conclusion

It is proved that the use of the drug Iodofol at the planning stage of pregnancy contributed to the normalization of the size of the thyroid gland.

Key words: thyroid pathology, pregnancy, potassium iodide, folic acid.

ARTICLES FROM CATEGORY
Support of educational events. Participation of World Medicine in the First Congress of Optometrists of Ukraine.
Cetirizine is an effective and safe antihistamine (literature review, results of clinical researches)
All-Ukrainian Scientific and Practical Conference “Aspects of Internal Medicine in Wartime 2024"

PROVE YOU ARE A MEDICAL PROFESSIONAL

Attention: This section is intended for healthcare professionals only. If you are not a medical professional, you can return to the main page by clicking the “No” option

CARD-NOTIFICATION OF AN ADVERSE DRUG REACTION AND/OR LACK OF EFFICACY OF THE MEDICINE

INFORMATION ABOUT THE PATIENT

SUSPECTED AR/LE

Suspected AR (describe each clinical manifestation of the AR with dates and times of onset and end and outcome)/Indication of the LE

INFORMATION ABOUT SUSPECTED MEDICINES

INFORMATION ABOUT RELATED MEDICINES

(with the exception of drugs used to correct the effects of AR/LE)
(concomitant diagnoses, laboratory and instrumental studies, allergy history, pregnancy with gestational age, method of conception, pregnancy outcome (if the pregnancy ended, the date of delivery, type of delivery, etc.)

Information about the messenger

INFORMATION ABOUT THE MEDICAL/PHARMACY SPECIALIST

(if not the notifier)

MESSAGE CARD for the patient

to provide the patient and/or his/her representative with information on adverse drug reactions and/or lack of efficacy of the drug

INFORMATION ABOUT THE PATIENT

Information about the suspected medicine

Information on the prescription of the suspected medicinal product

Information about the messenger

Information about the physician, healthcare facility and place of residence of the patient who had an adverse medicine reaction and/or lack of efficacy of the medicine

розробка сайту Estetic web design